On the public citation graph
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
0 signed · 1531 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2013.280319openalex-snapshot
Glioblastoma and Other Malignant Gliomas
inferredcites →https://doi.org/10.1016/s1470-2045(09)70025-7openalex-snapshot
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30194-8openalex-snapshot
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
inferredcites →https://doi.org/10.1038/s41571-018-0003-5openalex-snapshot
Current state of immunotherapy for glioblastoma
inferredcites →https://doi.org/10.1056/nejmoa043331openalex-snapshot
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
inferredcites →https://doi.org/10.1056/nejmoa1602252openalex-snapshot
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
inferredcites →https://doi.org/10.1093/brain/aww046openalex-snapshot
Corticosteroids compromise survival in glioblastoma
inferredcites →https://doi.org/10.1093/neuonc/noq001openalex-snapshot
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone
inferredcites →https://doi.org/10.1093/neuonc/nos273openalex-snapshot
Standards of care for treatment of recurrent glioblastoma—are we there yet?
inferredcites →https://doi.org/10.1093/neuonc/nox208openalex-snapshot
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
inferredcites →https://doi.org/10.1111/j.1750-3639.2009.00315.xopenalex-snapshot
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
inferredcites →https://doi.org/10.1158/2326-6066.cir-15-0151openalex-snapshot
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
inferredcites →https://doi.org/10.1200/jco.2008.19.8721openalex-snapshot
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
inferredcites →https://doi.org/10.1200/jco.2009.26.3541openalex-snapshot
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
inferredcites →https://doi.org/10.18632/aging.100797openalex-snapshot
Corticosteroids and immune checkpoint blockade
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4638324openalex-extracted
Multi-Omics Reveals the Impact of Cancer-Associated Fibroblasts on the Prognosisand Treatment Response of Glioblastoma
inferred← citeshttps://doi.org/10.2139/ssrn.4812979openalex-extracted
Toxoplasma Gondii Infection Supports the Infiltration of T Cells into Brain Tumors
inferred← citeshttps://doi.org/10.1001/jama.2020.5934openalex-snapshot
Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of Glioblastoma
inferred← citeshttps://doi.org/10.1001/jama.2023.0023openalex-snapshot
Glioblastoma and Other Primary Brain Malignancies in Adults
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.3284openalex-snapshot
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.0857openalex-snapshot
Results From the CheckMate 143 Clinical Trial
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.3161openalex-snapshot
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.4508openalex-snapshot
Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.4657openalex-snapshot
Appropriate Analysis of Duration of Response Data in Cancer Trials
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.4664openalex-snapshot
Appropriate Analysis of Duration of Response Data in Cancer Trials—Reply
inferred← citeshttps://doi.org/10.1002/14651858.cd012532.pub2openalex-snapshot
Anti-PD-1 and anti-PD-L1 antibodies for glioma
inferred← citeshttps://doi.org/10.1002/1878-0261.12790openalex-snapshot
Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study
inferred← citeshttps://doi.org/10.1002/1878-0261.13015openalex-snapshot
Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study
inferred← citeshttps://doi.org/10.1002/1878-0261.13162openalex-snapshot
Cadherin‐3 is a novel oncogenic biomarker with prognostic value in glioblastoma
inferred← citeshttps://doi.org/10.1002/1878-0261.13287openalex-snapshot
Elucidating tumour‐associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency
inferred← citeshttps://doi.org/10.1002/1878-0261.13678openalex-snapshot
Current status of precision oncology in adult glioblastoma
inferred← citeshttps://doi.org/10.1002/adfm.202425894openalex-snapshot
Harnessing Nanotheranostics‐Based Dendritic Cells Tracking Mature Tertiary Lymphoid Structures to Boost Anti‐Glioma Immunotherapy
inferred← citeshttps://doi.org/10.1002/adhm.202400925openalex-snapshot
Classical Monocytes Shuttling for Precise Delivery of Nanotherapeutics to Glioblastoma
inferred← citeshttps://doi.org/10.1002/adma.202208782openalex-snapshot
Dual Immunostimulatory Pathway Agonism through a Synthetic Nanocarrier Triggers Robust Anti‐Tumor Immunity in Murine Glioblastoma
inferred← citeshttps://doi.org/10.1002/adtp.202100046openalex-snapshot
Advanced Immunotherapy Approaches for Glioblastoma
inferred← citeshttps://doi.org/10.1002/advs.202407262openalex-snapshot
CD47 Knock‐Out Using CRISPR‐Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo
inferred← citeshttps://doi.org/10.1002/advs.202408323openalex-snapshot
Sequential Release HydroLipo System for STING Gene Epigenetic Reprogramming and Immune Activation in Glioblastoma
inferred← citeshttps://doi.org/10.1002/advs.202502271openalex-snapshot
Comprehensive Characterization of the Immune Microenvironment Based on Nested Resampling Machine Learning Framework Identifies TRAF3 Interacting Protein 3 as a Promising Regulator to Improve the Resistance to Immunotherapy in Glioma
inferred← citeshttps://doi.org/10.1002/advs.202521355openalex-snapshot
Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies
inferred← citeshttps://doi.org/10.1002/brb3.71648openalex-snapshot
Microbiota–Neuroinflammation Crosstalk in Primary Brain Tumors: Focus on Glioblastoma
inferred← citeshttps://doi.org/10.1002/btm2.10712openalex-snapshot
Immunotherapy against glioblastoma using backpack‐activated neutrophils
inferred← citeshttps://doi.org/10.1002/cac2.12539openalex-snapshot
Immunologic tumor microenvironment modulators for turning cold tumors hot
inferred← citeshttps://doi.org/10.1002/cai2.59openalex-snapshot
Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma
inferred← citeshttps://doi.org/10.1002/cam4.5467openalex-snapshot
Compassionate use of recombinant human IL‐7‐hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma
inferred← citeshttps://doi.org/10.1002/cam4.5681openalex-snapshot
Cellular and molecular features related to exceptional therapy response and extreme long‐term survival in glioblastoma
inferred← citeshttps://doi.org/10.1002/cam4.70689openalex-snapshot
Temporal Muscle Thickness as a Prognostic Marker in a Real‐Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging Analysis
inferred← citeshttps://doi.org/10.1002/cam4.71858openalex-snapshot
Modern Clinical Trials: Seamless Designs and Master Protocols
inferred← citeshttps://doi.org/10.1002/cam4.7218openalex-snapshot
Artificial neural network identified a 20‐gene panel in predicting immunotherapy response and survival benefits after anti‐PD1 / PD‐L1 treatment in glioblastoma patients
inferred← citeshttps://doi.org/10.1002/cam4.7362openalex-snapshot
Targeted agents in patients with progressive glioblastoma—A systematic meta‐analysis of randomized clinical trials
inferred← citeshttps://doi.org/10.1002/cbic.202400848openalex-snapshot
Challenges and Emerging Strategies of Immunotherapy for Glioblastoma
inferred← citeshttps://doi.org/10.1002/cncr.33378openalex-snapshot
Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial
inferred← citeshttps://doi.org/10.1002/cncr.34711openalex-snapshot
Top advances of the year: Neuro‐oncology
inferred← citeshttps://doi.org/10.1002/cncr.35935openalex-snapshot
Top advances of the year: The status of chimeric antigen receptor T cells in neuro‐oncology
inferred← citeshttps://doi.org/10.1002/cncr.70015openalex-snapshot
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort
inferred← citeshttps://doi.org/10.1002/cncr.70253openalex-snapshot
Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial
inferred← citeshttps://doi.org/10.1002/cnr2.1947openalex-snapshot
Immunotherapy: Advancing glioblastoma treatment—A narrative review of scientific studies
inferred← citeshttps://doi.org/10.1002/cti2.1283openalex-snapshot
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
inferred← citeshttps://doi.org/10.1002/ddr.22261openalex-snapshot
Targeted therapies for Glioblastoma multiforme (GBM): State‐of‐the‐art and future prospects
inferred← citeshttps://doi.org/10.1002/eji.202250257openalex-snapshot
Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment
inferred← citeshttps://doi.org/10.1002/glia.23883openalex-snapshot
Genetic driver mutations introduced in identical cell‐of‐origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade
inferred← citeshttps://doi.org/10.1002/iid3.1022openalex-snapshot
The CD2–CD58 axis: A novel marker predicting poor prognosis in patients with low‐grade gliomas and potential therapeutic approaches
inferred← citeshttps://doi.org/10.1002/jbt.70993openalex-snapshot
Exploring Novel Compounds and Nanocomplexes to Target Cellular and Molecular Interactions in the Glioblastoma Microenvironment
inferred← citeshttps://doi.org/10.1002/jex2.70181openalex-snapshot
Natural Killer Cell‐Derived Extracellular Vesicle Preparations Demonstrate Potent Antitumor Activity Against Human Glioblastoma In Vitro and In Vivo
inferred← citeshttps://doi.org/10.1002/mbo3.70431openalex-snapshot
The Microbiome in Glioblastoma: Mechanisms, Tumor–Immune Interactions, and Translational Perspectives
inferred← citeshttps://doi.org/10.1002/mco2.341openalex-snapshot
Cancer stem cells in brain tumors: From origin to clinical implications
inferred← citeshttps://doi.org/10.1002/mco2.458openalex-snapshot
Identification of RP11‐770J1.4 as immune‐related lncRNA regulating the CTXN1–cGAS–STING axis in histologically lower‐grade glioma
inferred← citeshttps://doi.org/10.1002/mco2.70686openalex-snapshot
Isocitrate Dehydrogenase‐Mutant Astrocytomas: Risk Stratification and Therapeutic Advance
inferred← citeshttps://doi.org/10.1002/mef2.61openalex-snapshot
Oncolytic viral therapy as promising immunotherapy against glioma
inferred← citeshttps://doi.org/10.1002/onco.13728openalex-snapshot
Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report
inferred← citeshttps://doi.org/10.1002/tox.24309openalex-snapshot
Identifying and validating necroptosis‐associated features to predict clinical outcome and immunotherapy response in patients with glioblastoma
inferred← citeshttps://doi.org/10.1002/wnan.1838openalex-snapshot
Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies
inferred← citeshttps://doi.org/10.1007/16833_2023_174openalex-snapshot
The Evolving Landscape of Monocyte/Macrophage System in Glioma
inferred← citeshttps://doi.org/10.1007/16833_2024_440openalex-snapshot
TIME Is Critical for Oncolytic Viral Therapies Against Solid Cancers
inferred← citeshttps://doi.org/10.1007/16833_2025_498openalex-snapshot
Immunotherapeutic Approaches in Glioblastoma
inferred← citeshttps://doi.org/10.1007/978-1-0716-4754-7_3openalex-snapshot
In Vivo Murine Model for Oncolytic Viral Therapy for Malignant Glioma
inferred← citeshttps://doi.org/10.1007/978-3-030-69170-7_12openalex-snapshot
Rodent Brain Tumor Models for Neuro-Oncology Research
inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_7openalex-snapshot
Immunotherapy for Neuro-oncology
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_240-1openalex-snapshot
Immunotherapy for Primary Cancers of Central Nervous System
inferred← citeshttps://doi.org/10.1007/978-3-030-98950-7_30openalex-snapshot
Tumor–Host Interactions in Malignant Gliomas
inferred← citeshttps://doi.org/10.1007/978-3-031-59341-3_7openalex-snapshot
Radiation Oncology in Glioblastoma (GBM)
inferred← citeshttps://doi.org/10.1007/978-3-031-74842-4_10openalex-snapshot
Understanding the Role of Cancer Stem Cells in Brain Tumor Pathogenesis
inferred← citeshttps://doi.org/10.1007/978-3-031-93894-8_10openalex-snapshot
Therapeutic Potential of Combining Receptor Tyrosine Kinase Inhibitor with Immune Checkpoint Blockade
inferred← citeshttps://doi.org/10.1007/978-3-032-00769-8_240openalex-snapshot
Immunotherapy for Primary Cancers of Central Nervous System
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_121-1openalex-snapshot
Gliome des Erwachsenenalters
inferred← citeshttps://doi.org/10.1007/978-981-99-8373-5_13openalex-snapshot
Advancement of Radiolabeled Exosomes in Brain Disorders
inferred← citeshttps://doi.org/10.1007/s00018-023-04788-7openalex-snapshot
CCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastoma
inferred← citeshttps://doi.org/10.1007/s00018-024-05300-5openalex-snapshot
Combination of tumor antigen drainage and immune activation to promote a cancer-immunity cycle against glioblastoma
inferred← citeshttps://doi.org/10.1007/s00018-025-05642-8openalex-snapshot
Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade
inferred← citeshttps://doi.org/10.1007/s00066-026-02525-0openalex-snapshot
Interactions and communications in the glioblastoma microenvironment: potential targets for chemo-/radiotherapy
inferred← citeshttps://doi.org/10.1007/s00115-023-01590-5openalex-snapshot
Immuntherapie gegen Gliome
inferred← citeshttps://doi.org/10.1007/s00259-024-06743-5openalex-snapshot
[18F]AlF-NOTA-PCP2: a novel PET/CT tracer for enhanced PD-L1 heterogeneity imaging and comparative analysis with [18F]AlF-NOTA-WL12 in glioblastoma xenografts
inferred← citeshttps://doi.org/10.1007/s00262-020-02769-4openalex-snapshot
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient
inferred← citeshttps://doi.org/10.1007/s00262-020-02801-7openalex-snapshot
Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment
inferred← citeshttps://doi.org/10.1007/s00262-021-02951-2openalex-snapshot
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
inferred← citeshttps://doi.org/10.1007/s00262-021-03130-zopenalex-snapshot
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
inferred← citeshttps://doi.org/10.1007/s00262-021-03131-yopenalex-snapshot
Pediatric glioblastoma: mechanisms of immune evasion and potential therapeutic opportunities
inferred← citeshttps://doi.org/10.1007/s00262-022-03184-7openalex-snapshot
Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma
inferred← citeshttps://doi.org/10.1007/s00262-022-03315-0openalex-snapshot
Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor
inferred← citeshttps://doi.org/10.1007/s00262-022-03349-4openalex-snapshot
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
inferred← citeshttps://doi.org/10.1007/s00262-022-03358-3openalex-snapshot
Interaction of glioma-associated microglia/macrophages and anti-PD1 immunotherapy
inferred← citeshttps://doi.org/10.1007/s00262-023-03366-xopenalex-snapshot
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
inferred← citeshttps://doi.org/10.1007/s00262-023-03381-yopenalex-snapshot
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00262-024-03774-7openalex-snapshot
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
inferred← citeshttps://doi.org/10.1007/s00262-025-03994-5openalex-snapshot
Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment
inferred← citeshttps://doi.org/10.1007/s00262-025-04098-wopenalex-snapshot
Simultaneous TGF-β and GITR pathway modulation promotes anti-tumor immunity in glioma
inferred← citeshttps://doi.org/10.1007/s00281-022-00945-5openalex-snapshot
A Conceptual Framework for Inducing T Cell-Mediated Immunity Against Glioblastoma
inferred← citeshttps://doi.org/10.1007/s00401-023-02654-1openalex-snapshot
“De novo replication repair deficient glioblastoma, IDH-wildtype” is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade
inferred← citeshttps://doi.org/10.1007/s00401-025-02937-9openalex-snapshot
Spatial transcriptomic analysis reveals lack of response to PD-1 blockade in recurrent glioblastoma
inferred← citeshttps://doi.org/10.1007/s00431-026-07131-xopenalex-snapshot
Systemic versus intracranial immunotherapy delivery in pediatric malignant brain tumors: a systematic review, meta-analysis, and meta-regression
inferred← citeshttps://doi.org/10.1007/s00432-025-06159-0openalex-snapshot
Developing and validating a prognostic disulfidptosis-related signature for glioblastoma: predicting radioresistance and synergestic effect with immunotherapy
inferred← citeshttps://doi.org/10.1007/s00508-026-02725-9openalex-snapshot
Evolving landscape of glioblastoma research
inferred← citeshttps://doi.org/10.1007/s00761-024-01473-7openalex-snapshot
Glioblastom – aktuelle Therapiekonzepte
inferred← citeshttps://doi.org/10.1007/s10014-021-00402-5openalex-snapshot
Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy
inferred← citeshttps://doi.org/10.1007/s10014-022-00431-8openalex-snapshot
Implications of immune cells in oncolytic herpes simplex virotherapy for glioma
inferred← citeshttps://doi.org/10.1007/s10072-024-07350-wopenalex-snapshot
A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives
inferred← citeshttps://doi.org/10.1007/s10143-024-02409-wopenalex-snapshot
Laser interstitial thermal therapy for recurrent glioblastomas: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s10143-024-02696-3openalex-snapshot
The future of neuro-oncology: precision medicine and targeted therapies
inferred← citeshttps://doi.org/10.1007/s10143-025-04043-6openalex-snapshot
Efficacy and safety of immune checkpoint inhibitors and mTOR inhibitors as targeted therapy for glioblastoma: A systematic review and meta-analysis of randomized clinical trials
inferred← citeshttps://doi.org/10.1007/s10147-021-02028-1openalex-snapshot
Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study
inferred← citeshttps://doi.org/10.1007/s10238-023-01159-1openalex-snapshot
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
inferred← citeshttps://doi.org/10.1007/s10555-021-09997-9openalex-snapshot
Glioma: molecular signature and crossroads with tumor microenvironment
inferred← citeshttps://doi.org/10.1007/s10555-022-10051-5openalex-snapshot
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications
inferred← citeshttps://doi.org/10.1007/s11011-023-01234-2openalex-snapshot
Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme
inferred← citeshttps://doi.org/10.1007/s11011-023-01333-0openalex-snapshot
Glioma hexokinase 3 positively correlates with malignancy and macrophage infiltration
inferred← citeshttps://doi.org/10.1007/s11033-024-09996-3openalex-snapshot
Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy
inferred← citeshttps://doi.org/10.1007/s11033-026-12216-9openalex-snapshot
Overcoming resistance in glioblastoma immunotherapy: lessons from the past and opportunities for the future
inferred← citeshttps://doi.org/10.1007/s11060-020-03684-5openalex-snapshot
Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies
inferred← citeshttps://doi.org/10.1007/s11060-020-03689-0openalex-snapshot
Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma
inferred← citeshttps://doi.org/10.1007/s11060-021-03721-xopenalex-snapshot
LAG-3 expression in the inflammatory microenvironment of glioma
inferred← citeshttps://doi.org/10.1007/s11060-021-03851-2openalex-snapshot
Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial
inferred← citeshttps://doi.org/10.1007/s11060-021-03859-8openalex-snapshot
Immune checkpoint inhibitors in GBM
inferred← citeshttps://doi.org/10.1007/s11060-021-03907-3openalex-snapshot
PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma
inferred← citeshttps://doi.org/10.1007/s11060-021-03930-4openalex-snapshot
Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma
inferred← citeshttps://doi.org/10.1007/s11060-022-03973-1openalex-snapshot
The roles of thermal and mechanical stress in focused ultrasound-mediated immunomodulation and immunotherapy for central nervous system tumors
inferred← citeshttps://doi.org/10.1007/s11060-022-04005-8openalex-snapshot
Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults
inferred← citeshttps://doi.org/10.1007/s11060-022-04049-wopenalex-snapshot
Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis
inferred← citeshttps://doi.org/10.1007/s11060-022-04148-8openalex-snapshot
Emerging systemic treatment options in meningioma
inferred← citeshttps://doi.org/10.1007/s11060-022-04162-wopenalex-snapshot
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis
inferred← citeshttps://doi.org/10.1007/s11060-022-04165-7openalex-snapshot
Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas
inferred← citeshttps://doi.org/10.1007/s11060-022-04221-2openalex-snapshot
Multiplatform molecular analysis of vestibular schwannoma reveals two robust subgroups with distinct microenvironment
inferred← citeshttps://doi.org/10.1007/s11060-023-04340-4openalex-snapshot
Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis
inferred← citeshttps://doi.org/10.1007/s11060-023-04456-7openalex-snapshot
Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma
inferred← citeshttps://doi.org/10.1007/s11060-024-04575-9openalex-snapshot
Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype
inferred← citeshttps://doi.org/10.1007/s11060-024-04593-7openalex-snapshot
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
inferred← citeshttps://doi.org/10.1007/s11060-024-04646-xopenalex-snapshot
Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition
inferred← citeshttps://doi.org/10.1007/s11060-024-04705-3openalex-snapshot
Imaging timing after surgery for glioblastoma: an evaluation of practice in Great Britain and Ireland (INTERVAL-GB)- a multi-centre, cohort study
inferred← citeshttps://doi.org/10.1007/s11060-024-04781-5openalex-snapshot
Exploring the prognostic value of BRMS1 + microglia based on single-cell anoikis regulator patterns in the immunologic microenvironment of GBM
inferred← citeshttps://doi.org/10.1007/s11060-024-04813-0openalex-snapshot
Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials
inferred← citeshttps://doi.org/10.1007/s11060-024-04873-2openalex-snapshot
The 5-factor modified frailty index as a prognostic factor for stereotactic radiosurgery in meningioma management
inferred← citeshttps://doi.org/10.1007/s11060-024-04881-2openalex-snapshot
Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions
inferred← citeshttps://doi.org/10.1007/s11060-024-04919-5openalex-snapshot
Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors
inferred← citeshttps://doi.org/10.1007/s11060-025-04957-7openalex-snapshot
Sonodynamic therapy with a single neoadjuvant, diffuse delivery of low-intensity ultrasound with 5-ALA in treatment naïve glioblastoma results in tumor-specific cytotoxic edema and increased apoptosis
inferred← citeshttps://doi.org/10.1007/s11060-025-05058-1openalex-snapshot
Current trends in reoperation for recurrent glioblastoma: a meta-analysis (2007–2023)
inferred← citeshttps://doi.org/10.1007/s11060-025-05131-9openalex-snapshot
Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma
inferred← citeshttps://doi.org/10.1007/s11060-025-05143-5openalex-snapshot
Cystic glioblastoma IDH-wildtype: genetic alterations and outcomes
inferred← citeshttps://doi.org/10.1007/s11060-025-05248-xopenalex-snapshot
Emerging therapies for glioblastoma
inferred← citeshttps://doi.org/10.1007/s11060-025-05250-3openalex-snapshot
Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas
inferred← citeshttps://doi.org/10.1007/s11060-025-05251-2openalex-snapshot
Neurotoxicity in central nervous system tumors treated with CAR T cell therapy: a review
inferred← citeshttps://doi.org/10.1007/s11060-025-05262-zopenalex-snapshot
Redefining the therapeutic landscape of glioblastomas and brain metastasis through cesium brachytherapy and low-kV intra-operative radiation therapy (IORT)
inferred← citeshttps://doi.org/10.1007/s11060-025-05315-3openalex-snapshot
Immunotherapy and targeted therapy for high grade gliomas: current and future directions
inferred← citeshttps://doi.org/10.1007/s11060-025-05395-1openalex-snapshot
Glioblastoma immunotherapy in the context of the aging immune system: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s11060-025-05414-1openalex-snapshot
Radiation immunodynamics: association of baseline and longitudinal cytokine levels during radiotherapy in glioblastoma with survival
inferred← citeshttps://doi.org/10.1007/s11060-026-05446-1openalex-snapshot
A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination
inferred← citeshttps://doi.org/10.1007/s11060-026-05461-2openalex-snapshot
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study
inferred← citeshttps://doi.org/10.1007/s11060-026-05632-1openalex-snapshot
Laser interstitial thermal therapy versus stereotactic radiosurgery for first-time treatment of recurrent glioblastoma: a retrospective single-center study
inferred← citeshttps://doi.org/10.1007/s11060-026-05635-yopenalex-snapshot
From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma
inferred← citeshttps://doi.org/10.1007/s11060-026-05768-0openalex-snapshot
The intersection of chemokine signaling with the hallmarks of cancer in glioblastoma
inferred← citeshttps://doi.org/10.1007/s11307-021-01667-0openalex-snapshot
In Vivo Evaluation of Near-Infrared Fluorescent Probe for TIM3 Targeting in Mouse Glioma
inferred← citeshttps://doi.org/10.1007/s11307-025-02037-wopenalex-snapshot
Metabolic Shift Mirrors GBM Immunity to Anti-PD-L1 Immunotherapy: A Deuterium MRS Study
inferred← citeshttps://doi.org/10.1007/s11604-023-01434-xopenalex-snapshot
The need of radiotherapy optimization for glioblastomas considering immune responses
inferred← citeshttps://doi.org/10.1007/s11654-022-00422-3openalex-snapshot
Immuntherapie und zielgerichtete Therapie von Gliomen
inferred← citeshttps://doi.org/10.1007/s11684-021-0902-1openalex-snapshot
Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s11864-021-00930-4openalex-snapshot
Current WHO Guidelines and the Critical Role of Genetic Parameters in the Classification of Glioma: Opportunities for Immunotherapy
inferred← citeshttps://doi.org/10.1007/s11864-024-01200-9openalex-snapshot
Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?
inferred← citeshttps://doi.org/10.1007/s11864-024-01211-6openalex-snapshot
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas
inferred← citeshttps://doi.org/10.1007/s11910-022-01176-9openalex-snapshot
Advances in Immunotherapies for Gliomas
inferred← citeshttps://doi.org/10.1007/s11910-023-01268-0openalex-snapshot
Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas
inferred← citeshttps://doi.org/10.1007/s11910-023-01315-wopenalex-snapshot
Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy
inferred← citeshttps://doi.org/10.1007/s11910-024-01338-xopenalex-snapshot
Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma
inferred← citeshttps://doi.org/10.1007/s11910-025-01477-9openalex-snapshot
Immunotherapies for Central Nervous System Tumors and their Neurologic Complications
inferred← citeshttps://doi.org/10.1007/s11912-020-01007-5openalex-snapshot
Current Advances in Immunotherapy for Glioblastoma
inferred← citeshttps://doi.org/10.1007/s11912-021-01157-0openalex-snapshot
Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature
inferred← citeshttps://doi.org/10.1007/s11912-022-01201-7openalex-snapshot
Newly Diagnosed Glioblastoma in Elderly Patients
inferred← citeshttps://doi.org/10.1007/s11912-023-01394-5openalex-snapshot
Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future
inferred← citeshttps://doi.org/10.1007/s11912-023-01417-1openalex-snapshot
Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
inferred← citeshttps://doi.org/10.1007/s11912-024-01519-4openalex-snapshot
Novel Clinical Trials and Approaches in the Management of Glioblastoma
inferred← citeshttps://doi.org/10.1007/s11912-024-01602-wopenalex-snapshot
Molecular Testing in Gliomas: What is Necessary in Routine Clinical Practice?
inferred← citeshttps://doi.org/10.1007/s12015-021-10199-7openalex-snapshot
Pluripotent Stem Cells: Cancer Study, Therapy, and Vaccination
inferred← citeshttps://doi.org/10.1007/s12017-021-08677-9openalex-snapshot
Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors
inferred← citeshttps://doi.org/10.1007/s12017-025-08830-8openalex-snapshot
From Gut to Brain: The Impact of Short-Chain Fatty Acids on Brain Cancer
inferred← citeshttps://doi.org/10.1007/s12032-022-01708-wopenalex-snapshot
Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches
inferred← citeshttps://doi.org/10.1007/s12094-022-02946-0openalex-snapshot
Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors
inferred← citeshttps://doi.org/10.1007/s12094-023-03245-yopenalex-snapshot
SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
inferred← citeshttps://doi.org/10.1007/s12094-026-04401-wopenalex-snapshot
Post-recurrence management of malignant glial brain tumors: therapeutic strategies, evidence and limitations, palliative care, terminal sedation, and end-of-life considerations
inferred← citeshttps://doi.org/10.1007/s12094-026-04453-yopenalex-snapshot
Advances and challenges in glioblastoma immunotherapy: a meta-analysis of immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s12254-021-00752-yopenalex-snapshot
ASCO 2021: Highlights in central nervous system tumors
inferred← citeshttps://doi.org/10.1007/s12254-022-00853-2openalex-snapshot
Best of ASCO 2022—central nervous system tumors
inferred← citeshttps://doi.org/10.1007/s12254-023-00879-0openalex-snapshot
ESMO 2022: spotlight on new emerging treatment options in central nervous system tumors
inferred← citeshttps://doi.org/10.1007/s12254-025-01085-wopenalex-snapshot
Primary central nervous system tumors: future directions in systemic treatment
inferred← citeshttps://doi.org/10.1007/s12264-022-00953-3openalex-snapshot
The Oncogenesis of Glial Cells in Diffuse Gliomas and Clinical Opportunities
inferred← citeshttps://doi.org/10.1007/s12312-026-01604-8openalex-snapshot
Immuntherapien bei primären Hirntumoren
inferred← citeshttps://doi.org/10.1007/s12561-022-09337-7openalex-snapshot
Building an External Control Arm for Development of a New Molecular Entity: An Application in a Recurrent Glioblastoma Trial for MDNA55
inferred← citeshttps://doi.org/10.1007/s12640-022-00606-3openalex-snapshot
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines
inferred← citeshttps://doi.org/10.1007/s12672-024-00944-yopenalex-snapshot
A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy
inferred← citeshttps://doi.org/10.1007/s12672-024-01544-6openalex-snapshot
Understanding serine and glycine metabolism in cancer: a path towards precision medicine to improve patient’s outcomes
inferred← citeshttps://doi.org/10.1007/s12672-024-01587-9openalex-snapshot
Novel signature of ferroptosis-related long non-coding RNA to predict lower-grade glioma overall survival
inferred← citeshttps://doi.org/10.1007/s12672-025-03395-1openalex-snapshot
Transcriptomic HEPN1 signatures predict treatment response in low grade glioma
inferred← citeshttps://doi.org/10.1007/s12672-025-03807-2openalex-snapshot
Current strategies and novel immunotherapeutic approaches for overcoming immune resistance in glioblastoma
inferred← citeshttps://doi.org/10.1007/s12672-025-04013-wopenalex-snapshot
Bibliometric evaluation of research trends and hotspots concerning the interaction between immune checkpoint inhibitors and glioma
inferred← citeshttps://doi.org/10.1007/s12672-026-04658-1openalex-snapshot
A PIK3CA and NF1 expression-based prognostic signature derived from Mendelian randomization identifies causal immune-regulatory determinants of glioblastoma outcomes
inferred← citeshttps://doi.org/10.1007/s12672-026-05210-xopenalex-snapshot
Precision reirradiation in recurrent CNS tumors integrating biology techniques and multimodal care
inferred← citeshttps://doi.org/10.1007/s13311-022-01207-wopenalex-snapshot
RAGE Inhibitors as Alternatives to Dexamethasone for Managing Cerebral Edema Following Brain Tumor Surgery
inferred← citeshttps://doi.org/10.1007/s13311-022-01251-6openalex-snapshot
Updates in IDH-Wildtype Glioblastoma
showing the first 200 of 1515 · page through all 1515
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.